Clinical Development
| ACE Pharmaceuticals | ||
Our laboratory is a certified, independently operating analytical laboratory, providing advanced and sophisticated analytical services with experienced professionals and state-of-the-art instrumentation. |
Analysis of active ingredients as such, in blends and finished products such as soft and hard gel caps, tablets and capsules. |
Primary packaging - bottling of tablets and capsules. |
ACE's up-to-date premises for the manufacturing of clinical trial medication. |
||
| AltraBio | ||
Bridge the gap between biologists, statisticians and informaticians. |
Detect outliers and quality issues that cloud your data. |
Find the needles in your haystack - AltraBio provides expertise in state-of-the-art and innovative life science data analysis and interpretation. |
Place your results in the context of current biomedical knowledge. |
Identify new subgroups in your population. |
|
| BioScience Business Resources | ||
Array-based technology platforms incorporating novel protein and nucleic acid biomarkers are increasingly being adopted by mainstream diagnostic testing laboratories. |
Automated testing platforms are now available for even the most esoteric assays, enabling the adoption of those tests into routine testing laboratories. |
Biosensor technology is enabling the delivery of diagnostic tests based on novel biomarkers at the point of care. |
| Europa Bioproducts | ||
Europa Bioproducts specialises in the distribution of enzymes, kits and reagents used in the characterisation and analysis of the glycosylation patterns of therapeutic proteins and monoclonal antibodies. |
Post-translational modification is important to characterise and monitor because glycosylation has a significant impact on the efficacy, pharmokinetics and safety of the drug. |
Our products allow companies to perform oligosaccharide (glycan) profiling, oligosaccharide (glycan) sequencing and monosaccharide composition. |
We have 2-AA (for monosaccharide composition), 2-AB (for oligosaccharide / glycan profiling) and DMB (for sialic acids) Signal labelling kits. |
Preliminary identification can be achieved by calibrating the column with a 2-AB labelled dextran ladder and comparing retention times to known standards or databases. |
|
| FOCUS Clinical Drug Development | ||
FOCUS Clinical Drug Development is an independent full-service CRO that specialises in exploratory clinical drug development and integrated proof of concept (PoC) packages. |
FOCUS's Neuss Unit has performed >600 Ph I-III studies, more than 80 first-in-man studies (NCE / NBE) and 38 Ph I studies in Japanese subjects since 1997. |
FOCUS headquarters in Neuss, Germany. |
FOCUS can progress your development candidate from preclinical / discovery stage to clinical PoC in the most timely and economical fashion, via an integrated project management. |
FOCUS Immunology offers a range of services for exploratory drug development. |
|
| LanthioPep | ||
LanthioPep increases the in vivo stability of therapeutic and diagnostic imaging peptides by introducing thioether bridges in these peptides. |
LanthioPep’s thioether-bridge technology endows peptides with intrinsic in vivo stability thus creating new prospects for unstable peptide drug candidates. |
LanthioPep has introduced thioether bridges into a broad range of peptides, including peptide hormones and diagnostic imaging peptides. |
LanthioPep is developing its own stabilised peptide therapeutics and diagnostic imaging candidates. |
||
| VIBevents | ||
Our fifth annual Pharmacovigilance and Risk Management conference will be held 1-2 December 2009 in Brussels, Belgium. |
The conference will bring together major pharma and biotech manufacturers, as well as regulators, to discuss the important issues of pharmacovigilance and risk management. |
This two-day conference will ensure you effectively manage risk management with current medicines to mitigate any risks to patients. |
